Evidence map›Paper›PMID 26959119›Full record

ArticleOncotarget2016

Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.

Miriam Mints, Muhammad Mushtaq, Natalia Iurchenko, Larysa Kovalevska, Maria C Stip, Daria Budnikova, Sonia Andersson, Ludmila Polischuk, Lubov Buchynska, Elena Kashuba

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Construction of a Competitive Endogenous RNA Network in Uterine Corpus Endometrial Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  12. Article
  13. Article
  14. Mitochondrial ribosomes in cancer.Seminars in cancer biology · 2017
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Miriam MintsDepartment of Women's and Children's Health (KBH), Karolinska Institutet, Stockholm, 17176, Sweden.
Muhammad MushtaqDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden.
Natalia IurchenkoR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.
Larysa KovalevskaR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.
Maria C StipDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden.
Daria BudnikovaR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.
Sonia AnderssonDepartment of Women's and Children's Health (KBH), Karolinska Institutet, Stockholm, 17176, Sweden.
Ludmila PolischukR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.
Lubov BuchynskaR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.
Elena KashubaDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden.
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology · UAKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) is one of the most frequent causes of cancer death among women in developed countries. Histopathological diagnosis and imaging techniques for EC are limited, thus new prognostic markers are needed to offer patients the best treatment and follow-up.In the present paper we showed that the level of mitochondrial ribosomal protein MRPS18-2 (S18-2) increased in EC compared with the normal endometrium and hyperplasia, based on a study of 42 patient biopsies. Importantly, high expression of free E2F1 in EC correlates well with high S18-2 expression. The EC cell line HEC-1-A, which overexpresses S18-2 constitutively, showed an increased proliferation capacity in vitro and in vivo (in SCID mice). Moreover, pan-keratin, beta-catenin and E-cadherin signals are diminished in these cells, compared to the parental HEC-1-A line, in contrast to vimentin signal that is increased. This may be associated with epithelial-mesenchymal cell transition (EMT).We conclude that high expression of S18-2 and free E2F1, and low pan-keratin, beta-catenin, and E-cadherin signals might be a good set of prognostic markers for EC.

Indexed as

AdenocarcinomaAnimalsAntigens, CDbeta CateninBiomarkers, TumorCadherinsE2F1 Transcription FactorEndometrial NeoplasmsFemaleHeterograftsHumansKeratinsMiceMice, SCIDRibosomal ProteinsAntigens, CDbeta CateninBiomarkers, TumorCadherinsCDH1 protein, humanCTNNB1 protein, humanE2F1 protein, humanE2F1 Transcription FactorKeratinsRibosomal Proteinsribosomal protein S18cell transformationE2F1endometrial cancermitochondrial ribosomal protein MRPS18-2prognostic markers

Identifiers

PMID26959119
PMCPMC5008351
OpenAlexW2342104623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.